Beranda › Meningioma › Ohio
Uji klinis Meningioma di Ohio
7 studi untuk Meningioma mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- dan 30 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT02523014A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- The Ohio State University College of Medicine (OSUCOM), Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07428616RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07150806Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Mayfield Brain and Spine, Cincinnati
- Kettering Health, Kettering
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
Menerima pesertaFase 1/2
Usia 4 hingga 39 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT05278208Cognitive Status After Removal of Skull Base Meningioma
- Ohio State University Wexner Medical Center, Columbus
Menerima pesertaStudi observasional
Usia 18 hingga 89 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT04635657Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- UH Cleveland Medical Center, Cleveland
- Ohio State University, Columbus
Menerima pesertaFase 1/2
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT05636618Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.